Literature DB >> 15653507

Stat3 dimerization regulated by reversible acetylation of a single lysine residue.

Zheng-Long Yuan1, Ying-Jie Guan, Devasis Chatterjee, Y Eugene Chin.   

Abstract

Upon cytokine treatment, members of the signal transducers and activators of transcription (STAT) family of proteins are phosphorylated on tyrosine and serine sites within the carboxyl-terminal region in cells. We show that in response to cytokine treatment, Stat3 is also acetylated on a single lysine residue, Lys685. Histone acetyltransferase p300-mediated Stat3 acetylation on Lys685 was reversible by type I histone deacetylase (HDAC). Use of a prostate cancer cell line (PC3) that lacks Stat3 and PC3 cells expressing wild-type Stat3 or a Stat3 mutant containing a Lys685-to-Arg substitution revealed that Lys685 acetylation was critical for Stat3 to form stable dimers required for cytokine-stimulated DNA binding and transcriptional regulation, to enhance transcription of cell growth-related genes, and to promote cell cycle progression in response to treatment with oncostatin M.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653507     DOI: 10.1126/science.1105166

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  331 in total

1.  Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling.

Authors:  Sirichat Kaowinn; Seung Won Jun; Chang Seok Kim; Dong-Myeong Shin; Yoon-Hwae Hwang; Kyujung Kim; Bosung Shin; Chutima Kaewpiboon; Hyeon Hee Jeong; Sang Seok Koh; Oliver H Krämer; Randal N Johnston; Young-Hwa Chung
Journal:  Cell Oncol (Dordr)       Date:  2017-08-03       Impact factor: 6.730

Review 2.  Regulation of the inflammatory response of vascular endothelial cells by EPAC1.

Authors:  Euan Parnell; Brian O Smith; Timothy M Palmer; Anna Terrin; Manuela Zaccolo; Stephen J Yarwood
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Increased acetylation in the DNA-binding domain of TR4 nuclear receptor by the coregulator ARA55 leads to suppression of TR4 transactivation.

Authors:  Shaozhen Xie; Jing Ni; Yi-Fen Lee; Su Liu; Gonghui Li; Chih-Rong Shyr; Chawnshang Chang
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

4.  Editorial: HDAC inhibition begets more MDSCs.

Authors:  Pavan Reddy
Journal:  J Leukoc Biol       Date:  2012-05       Impact factor: 4.962

5.  A phosphorylation-acetylation switch regulates STAT1 signaling.

Authors:  Oliver H Krämer; Shirley K Knauer; Georg Greiner; Enrico Jandt; Sigrid Reichardt; Karl-Heinz Gührs; Roland H Stauber; Frank D Böhmer; Thorsten Heinzel
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

Review 6.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

7.  Histone deacetylase 3 suppresses Erk phosphorylation and matrix metalloproteinase (Mmp)-13 activity in chondrocytes.

Authors:  Lomeli R Carpio; Elizabeth W Bradley; Jennifer J Westendorf
Journal:  Connect Tissue Res       Date:  2016-09-23       Impact factor: 3.417

8.  Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation.

Authors:  Nagalakshmi Nadiminty; Wei Lou; Soo Ok Lee; Xin Lin; Donald L Trump; Allen C Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

Review 9.  Epigenomics and breast cancer.

Authors:  Pang-Kuo Lo; Saraswati Sukumar
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

10.  XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.

Authors:  Yan Cheng; Michael P Holloway; Kevin Nguyen; Dilara McCauley; Yosef Landesman; Michael G Kauffman; Sharon Shacham; Rachel A Altura
Journal:  Mol Cancer Ther       Date:  2014-01-15       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.